Patisiran – September 2023

• Brand names:
  • Onpattro®
• Pharmaceutical Company:
  • Alnylam Australia Pty Ltd
• Condition/Indication: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)
• Meeting Date: September 2023
• Public Summary Document (PSD) July 2023 September 2023 December 2023 PBAC Meetings - (PDF 0.9MB)
• Public Summary Document (PSD) July 2023 September 2023 December 2023 PBAC Meetings - (Word 0.5MB)

Related Public Summary Documents

• Patisiran – July 2023
• Patisiran – December 2023